The recent analytical report published by Markntel Advisors (a leading consulting, data analytics, and market research firm), EMEA Liquid Biopsy Market comprises a detailed study of critical and major aspects of market dynamics, i.e. market trends, size, forecasts, growth factors, challenges, and competitor landscape. The research company provides an extensive range of strategic reports on diverse industry verticals to substantial and varied client bases, including multinational corporations, financial institutions, governments, and individuals, among others.

EMEA Liquid Biopsy Industry Analytical Overview (2023-2028): Drivers, Opportunities, Challenges, and Trends,

According to the latest report, EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28.  The report significantly addressed considerable changes, gap analyses, and competitive studies using qualitative and quantitative data. These include the widespread segmentation, geography, and recent developments, entailing information on the fluctuation in the demand, sales, revenue, and other parameters experienced and expected in the industry for the forecasting year i.e. 2023 to 2028.

In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.

Download Report Sample PDF - https://www.marknteladvisors.com/query/request-sample/emea-liquid-biopsy-market.html

What is Included in EMEA Liquid Biopsy Market Segmentation?

The report has segmented the market into the following categories:

By Product and Services

• Equipment
• Assay Kits
• Services

By Circulating Biomarker

• Circulating Tumour Cell (CTC)
• Circulating Tumour DNA (ctDNA)
• Cell Free DNA (cfDNA)
• Extracellular Vesicle (EVS)

By Technology

• Multi gene analysis by Next Generation Sequencing (NGS)
• Single gene analysis by Polymer chase reaction (PCR)

By Sample Type

• Blood
• Urine
• Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)

Blood Sample-based Testing dominated the EMEA Liquid Biopsy Market during the historical years, as it is highly preferred by cancer patients owing to its least invasive nature & reduced risk of incision into the body. The blood samples can be used to detect various biomarkers like ctDNA, CTC, etc., and also allows for reducing the cost & time for the diagnosis. Further, the collection of blood samples is the most convenient method of diagnosis & has been majorly used for the detection of brain, lung, and breast cancers across the region, as it is one of the most painless methods of cancer detection. In addition to this, it can also detect the recurrence of cancer after treatment & helps in early detection & blood-based tests ongoing research for cancer is expected to drive the market in upcoming years.

By Application

• By Cancer Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma cancer
  • Others (Pancreatic, Liver, etc.)
• By Non Cancer Application
  • Non Invasive Parental Testing
  • Organ Transplantation
  • Infectious Diseases
• By Clinical Application
  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

By End User

• Hospital and Physician laboratories
• Reference Laboratories
• Academic & Research Centre

By Country

• Germany
• The UK
• France
• Italy
• Spain
• Saudi Arabia
• The UAE
• Egypt
• South Africa
• Rest of Europe Middle East & Africa

 ("Kindly use your official email ID for all correspondence to ensure seamless engagement and access to exclusive benefits, along with prioritized support from our sales team.")

Access the Complete Report for An In-Depth Analysis - https://www.marknteladvisors.com/research-library/emea-liquid-biopsy-market.html

Key Factor Driver EMEA Liquid Biopsy Industry Growth by 2028

Prevalence in the Number of Cancer Patients Would Generate the Demand for Liquid Biopsy – Cancer has been a chronic disease over the past years & would continue to ascend in the forecasting year as well, owing to the increasingly sedentary lifestyle, smoking, and drinking habit of the individual, which would require better diagnostic facilities, treatment, and care for the patients. The continuous boost in the number of cancer patients emphasizes the need for accurate & convenient diagnostic systems for early cancer detection. Consequently, with the rising number of cancer patients, especially across Turkey, France, Denmark, etc., the usage of Liquid Biopsy is also uplifting. The advantages of liquid biopsy, like lower cost, early prognosis, therapy monitoring, etc., have further enhanced their adoption over conventional diagnostic methods to detect urothelial carcinoma, non-urological cancers, and other blood cancers.

Who are the Key Players Operating in the EMEA Liquid Biopsy Industry?

The top companies of the EMEA Liquid Biopsy market ruling the industry are: 

• Thermofisher Scientific
• Hoffmann-La Roche Ltd
• Sysmex Corporation
• Qiagen N.V.
• Guardant Health
• Bio Rad
• Neo Genomics
• Epigenomics
• Menarini-Silicon Biosystems
• Agena Bioscience Inc.
• Silicon Biosystems
• Pathway Genomics Corporation
• Others (Myraid Genetics, Illumina Inc.,etc)

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address

Click Here to Connect with Our Expertise - https://www.marknteladvisors.com/query/talk-to-our-consultant/emea-liquid-biopsy-market.html

Key Objectives of Choosing Markntel Advisor’s Report

• Focused Industry Expertise
• Diverse Report Offerings
• Personalized Research Solutions
• Robust Research Methodology
• In-depth Report Coverage
• Tracking Technological Advancements
• Comprehensive Value-Chain Analysis
• Discovering Market Opportunities
• Analysing Growth Trajectories
• Assured Quality Insights
• Dedicated After-Sales Support

FAQs (Frequently Ask Questions)

1. What are the industry’s overall statistics or estimates including CARG and USD Value of the forecasting years?
2. What are the trends influencing the current scenario of the EMEA Liquid Biopsy Market?
3. What are the key factors that would propel and hinder the industry?
4. Which geographical area dominates the EMEA Liquid Biopsy industry?
5. Which is the Leading segment in the market?

About US:

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

For Media Inquiries, Please Contact: 

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511 

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India